Abstract:
Efficient thrombolysis in time is crucial for prognostic improvement of patients with acute arterial thromboembolic disease, while limitations and complications still exist in conventional thrombolytic treatment methods. Herein, our study sought to investigate a novel dual-mode strategy that integrated ultrasound (US) and near-infrared light (NIR) with establishment of hollow mesoporous silica nanoprobe (HMSN) which contains Arginine-glycine-aspartate (RGD) peptide (thrombus targeting), perfluoropentane (PFP) (thrombolysis with phase-change and stable cavitation) and indocyanine green (ICG) (thrombolysis with photothermal conversion). HMSN is used as the carrier, the surface is coupled with targeted RGD to achieve high targeting and permeability of thrombus, PFP and ICG are loaded to achieve the collaborative diagnosis and treatment of thrombus by US and NIR, so as to provide a new strategy for the integration of diagnosis and treatment of arterial thrombus. From the in vitro and in vivo evaluation, RGD/ICG/PFP@HMSN can aggregate and penetrate at the site of thrombus, and finally establish the dual-mode directional development and thrombolytic treatment under the synergistic effect of US and NIR, providing strong technical support for the accurate diagnosis and treatment of arterial thrombosis.
摘要:
及时有效的溶栓对于改善急性动脉血栓栓塞性疾病患者的预后至关重要。而常规溶栓治疗方法仍存在局限性和并发症。在这里,我们的研究试图研究一种新的双模式策略,整合超声(US)和近红外光(NIR)与建立中空介孔二氧化硅纳米探针(HMSN),其中含有精氨酸-甘氨酸-天冬氨酸(RGD)肽(血栓靶向),全氟戊烷(PFP)(具有相变和稳定空化的溶栓)和吲哚菁绿(ICG)(具有光热转化的溶栓)。HMSN作为载体,表面与靶向RGD结合以实现血栓的高靶向性和渗透性,通过加载PFP和ICG,以实现US和NIR对血栓的协同诊断和治疗。从而为动脉血栓的一体化诊治提供新的策略。从体外和体内评估来看,RGD/ICG/PFP@HMSN可聚集并穿透血栓部位,最后建立了US和NIR协同作用下的双模式定向发展和溶栓治疗,为动脉血栓的准确诊断和治疗提供有力的技术支持。